Analgesic use before and after oral anticoagulant initiation - A population-based study in Finland

European Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2015, Pages 723-732

  Ilomäki, Jenni ^a   Helin Salmivaara, Arja ^b,c   Huupponen, Risto ^b,d   Rikala, Maria ^b   Kirkpatrick, Carl M ^a   Korhonen, Maarit Jaana ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF TURKU   (Finland)

^c HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Analgesic; Anticoagulants; Drug interactions; NSAIDs; Pharmacoepidemiology

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; APIXABAN; BUPRENORPHINE; CODEINE; DABIGATRAN; FENTANYL; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; RIVAROXABAN; TRAMADOL; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; DRUG USE; EMBOLISM PREVENTION; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REIMBURSEMENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED; CROSSOVER PROCEDURE; DRUG INTERACTION; MIDDLE AGED; ODDS RATIO; ORAL DRUG ADMINISTRATION; RISK; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FINLAND; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK;

EID: 84953638281     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1836-9     Document Type: Article

References (43)

1. Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315-328
2. Antoniazzi S, Berdaï D, Conti V (2014) Risk of major bleeding and the standard doses of dabigatran. Eur J Intern Med 25:e73-e75
3. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M (2011) Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 42:2431-2435
4. de Abajo FJ, Gil MJ, Bryant V, Timoner J, Oliva B, García-Rodríguez LA (2013) Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol 69:691-701
5. Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K (2009) The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 41:619-628
6. Schelleman H, Brensinger CM, Bilker WB, Hennessy S (2011) Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 6:e21447
7. Gagne JJ, Maio V, Rabinowitz C (2008) Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 33:141-151
8. Malone D, Hutchins DS, Haupert H, Hansten P, Duncan B, Van Bergen RC, Solomon SL, Lipton RB (2005) Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 62:1983-1991
9. Roughead EE, Kalisch LM, Barratt JD, Gilbert AL (2010) Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol 70:252-257
10. Cheetham TG, Levy G, Niu F, Bixler F (2009) Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 43:1765-1773
11. Pottegård A, Meegaard PM, Holck LH, Christensen RD, Madsen H, Hallas J (2013) Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. Eur J Clin Pharmacol 69:641-646
12. Zhang Q, Bal-dit-Sollier C, Drouet L, Simoneau G, Alvarez J-C, Pruvot S, Aubourg R, Berge N, Bergmann J-F, Mouly S, Mahé I (2011) Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol 67:309-314
13. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE (1998) Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 479:657-662
14. Schulman S (2014) Advantages and limitations of the new anticoagulants. J Intern Med 275:1-11
15. Cohen D (2014) Concerns over data in key dabigatran trial. Br Med J 349:g4747
16. Samoš M, Stančiaková L, Ivanková J, Staško J, Kovář F, Dobrotová M, Galajda P, Kubisz P, Mokáň M (2015) Monitoring of dabigatran therapy using Hemoclot Thrombin Inhibitor assay in patients with atrial fibrillation. J Thromb Thrombolysis 39:95-100
17. Chin PK, Patterson DM, Zhang M, Jensen BP, Wright DF, Barclay ML, Begg EJ (2014) Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 78:630-638
18. Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL (2015) Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 17:187-193
19. Savelieva I, Camm AJ (2014) Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 37:32-47
20. Deftereos S, Anatoliotakis N, Giannopoulos G, Kaoukis A, Mavri M, Pyrgakis V, Stefanadis C (2012) Novel direct factor IIa and Xa inhibitors: mechanisms of action and preclinical studies. Curr Clin Pharmacol 7:149-165
21. Hellwig T, Gulseth M (2013) Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother 47:1478-1487
22. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators RE-LY (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321-328
23. Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ (2014) A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 78:599-609
24. Wang Y, Bajorek B (2014) New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 13:175-189
25. Masotti L, Lorenzini G, Seravalle C, Panigada G, Landini G, Cappelli R, Schulman S (2014) Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis. doi: 10.1007/s11239-014-1112-3
26. Vanden Daelen S, Peetermans M, Vanassche T, Verhamme P, Vandermeulen E (2015) Monitoring and reversal strategies for new oral anticoagulants. Expert Rev Cardiovasc Ther 13:95-103
27. Lindh JD, Andersson ML, Mannheimer B (2014) Adherence to guidelines for avoiding drug interactions associated with warfarin - a nationwide Swedish register study. PLoS One 9:e97388
28. Jobski K, Enders D, Amann U, Suzart K, Wallander MA, Schink T, Garbe E (2014) Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital. Eur J Clin Pharmacol 70:975-981
29. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86-94
30. WHO Collaborating Centre for Drug Statistics Methodology (2015) The anatomical therapeutic chemical classification system. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. http://www.whocc.no/atcddd/. Accessed Jan 12, 2015
31. Social Insurance Institution of Finland (2014) Limited basic reimbursability for certain medicines. Social Insurance Institution of Finland. http://www.kela.fi/laakkeet-ja-laakekorvaukset-rajoitetun-korvattavuuden-alkamisajat. Accessed Oct 10, 2014
32. Trujillo T, Dobesh PP (2014) Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs 74:1587-1603
33. Virjo I, Mäkelä K, Aho J, Kalliola P, Kurunmäki H, Uusitalo L, Valli M, Ylinen S (2010) Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. Scand J Prim Health Care 28:237-241
34. Finnish Medicines Agency Fimea, Social Insurance Institution of Finland (2013) Finnish statistics on medicines 2012. Fimea and Social Insurance Institution of Finland, Helsinki
35. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728-738
36. Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE (2012) Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res 130:147-151
37. Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, Rehm J, Prins MH (2014) Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174:947-953
38. Friedman RJ, Kurth A, Clemens A, Noack H, Eriksson B, Caprini JA (2012) Dabigatran etexilate and concomitant use of non-steroidal antiinflammatory. Thromb Haemost 108:183-190
39. Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 63:469-476
40. Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM (2013) The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol 6:677-695
41. Working group appointed by the Finnish Medical Society Duodecim and the Finnish Orthopaedic Association (2011) Hip fracture: current care guideline. The Finnish Medical Society Duodecim, Helsinki
42. Working group appointed by the Finnish Medical Society Duodecim and the Finnish Orthopaedic Association (2012) Osteoarthritis: current care guideline. The Finnish Medical Society Duodecim, Helsinki
43. Koffeman AR, Valkhoff VE, Celik S, W't Jong G, Sturkenboom MC, Bindels PJ, van der Lei J, Luijsterburg PA, Bierma-Zeinstra SM (2014) High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract 64:e191-e198